On June 3, 2026, longevity biotech startup NewLimit announced the closing of a $435 million Series C funding round. The round was led by Peter Thiel’s Founders Fund, with existing backers Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners participating again, and new investors including Thrive Capital, Greenoaks, and Quiet Capital joining. According to The Wall Street Journal, the round valued NewLimit at $3.1 billion, a more than threefold increase from a year ago.
The company's co-founder is none other than Brian Armstrong, the founder and CEO of Coinbase. In 2021, Armstrong, together with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel, invested $110 million to establish NewLimit in South San Francisco. With this latest funding, NewLimit revealed that it has achieved breakthrough research results and is now advancing longevity medicine into human clinical trials. The company's first drug, targeting alcohol-related liver disease, is expected to begin clinical trials next year.
Reprogramming Cell Age: Making Age Reversal Possible
NewLimit's core mission is "reprogramming cell age so that humans can enjoy longer healthspans." The company states, “As we age, cell function declines, making us more susceptible to disease. Aging was once thought inevitable, but emerging science shows it can be reversed at the cellular level.” The scientific foundation dates back to 2006, when Japanese scientist Shinya Yamanaka discovered that activating just a few specific transcription factors can reprogram adult cells into a youthful, embryonic stem cell-like state. These “Yamanaka factors” earned him the 2012 Nobel Prize in Physiology or Medicine.
Yamanaka’s work proved for the first time that cell age is not irreversible. NewLimit builds on this by developing drugs that activate specific transcription factor genes to reprogram the epigenome to a younger state. However, identifying the right combinations of transcription factors—the “payloads”—for different cell types remains the central scientific challenge.
Targeting Accelerated Aging in the Liver
NewLimit’s go-to-market strategy is to first validate its approach with a specific disease, gain regulatory approval, and then expand to broader applications. The first indication is alcohol-related liver disease. CEO Jacob Kimmel describes liver disease as a form of “accelerated aging” that reflects the universal aging process in a faster, more severe form. The planned clinical trials next year represent a milestone for longevity medicine moving from theory to practice.
Billionaire Bet on Immortality: Thiel, Altman, Bezos
NewLimit is not alone in the quest to prolong life. In 2022, Sam Altman invested $180 million in Retro Biosciences, which is also developing drugs to rejuvenate aging cells; the company recently disclosed a valuation of $1.8 billion. Another venture, Altos Labs, reportedly backed by Jeff Bezos, launched in 2022 with $3 billion and has since raised nearly twice that amount.
Peter Thiel has openly expressed his deep aversion to death, repeatedly stating that “death is the greatest enemy of humanity, yet we have come to accept it as a law of nature.” From Thiel to Altman to Bezos, the world’s wealthiest individuals are pouring billions into anti-aging research. When wealth and power reach the summit, time becomes the only true adversary—and the one luxury money cannot buy.
